Advanced Molecular Imaging
& Theranostic Solutions
Innovative PET imaging and theranostic technologies supporting targeted molecular imaging, oncology diagnostics, and precision nuclear medicine applications.
Precision PET Imaging Applications
AMS provides advanced PET & theranostic solutions utilizing Gallium-68 technologies for targeted molecular imaging, neuroendocrine tumor visualization, prostate cancer imaging, and precision diagnostic applications.
Ga-68 Technology
Advanced Gallium-68 radiolabelling workflow optimized for modern PET imaging applications.
Targeted Imaging
Specialized molecular targeting solutions for oncology and neuroendocrine diagnostics.
Theranostic Workflow
Integrated imaging and therapy approach supporting precision nuclear medicine.
PET Imaging Product Portfolio
Tc-PSMA, 20mgr
PSMA-targeted radiopharmaceutical developed for molecular imaging and diagnosis of metastatic prostate cancer applications.
- PSMA-T4 20 µg composition
- Prostate cancer targeting
- Advanced molecular imaging
- High diagnostic potential
Tc-Tecktroyd, 16mgr
Somatostatin receptor targeting radiopharmaceutical for neuroendocrine tumor imaging and molecular diagnostic applications.
- Targets somatostatin receptors
- Neuroendocrine tumor imaging
- High-resolution imaging quality
- Tc-based imaging workflow
Peptide Radiolabelling Solutions
PSMA kit for 68Ga labelling
Sterile freeze-dried peptide kit developed for Gallium-68 radiolabelling applications in advanced prostate cancer molecular imaging.
- PSMA-11 composition
- Endotoxin free formulation
- 12 months shelf life
- Designed for 68Ga labelling
DOTATATE SA 40 μg
Direct 68Ga radiolabelling kit intended for neuroendocrine tumor molecular imaging and targeted theranostic workflows.
- DOTATATE trifluoroacetate
- Sterile freeze-dried solid
- Ga-68 direct radiolabelling
- Optimized PET imaging workflow